Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 12/20 | 0.43 |
| ▸ | EGFR | P00533 | 12/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.37 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 2/20 | 0.36 |
| ▸ | CIT | O14578 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | GAK | O14976 | 1/20 | 0.36 |
| ▸ | STK10 | O94804 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | YES1 | P07947 | 1/20 | 0.36 |
| ▸ | LYN | P07948 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | HCK | P08631 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14017708 | 0.86 | AAK1 (0.44) | ERBB2EGFRAAK1MET | |
| SCHEMBL4819515 | 0.76 | MET (0.57) | ERBB2EGFRAAK1MET | |
| SCHEMBL4813480 | 0.74 | ERBB2 (0.54) | ERBB2EGFRAAK1METLCK | |
| SCHEMBL1219397 | 0.71 | AAK1 (0.61) | ERBB2EGFRAAK1MET | |
| SCHEMBL21561513 | 0.70 | ERBB2 (0.41) | ERBB2EGFRAAK1TTBK1TTBK2 | |
| SCHEMBL1220750 | 0.63 | ERBB2 (0.77) | ERBB2EGFRAAK1LCKKDR | |
| SCHEMBL1220220 | 0.61 | ERBB2 (0.77) | ERBB2EGFRAAK1LCKKDR | |
| SCHEMBL1219763 | 0.60 | ERBB2 (1.00) | ERBB2EGFRAAK1LCKKDR | |
| SCHEMBL1219490 | 0.60 | ERBB2 (1.00) | ERBB2EGFRAAK1LCKKDR | |
| SCHEMBL25401088 | 0.57 | TP53 (0.69) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | ERBB2 32/4885EGFR 408/4885AAK1 204/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | ERBB2 162/4885EGFR 1009/4885AAK1 120/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | ERBB2 32/4885EGFR 408/4885AAK1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.